Novel Carrier Peptide
- Summary
- A cell penetrating peptide designated Xentry derived from the X-protein of the hepatitis B virus
- Technology Benefits
- It is small compared to other known peptides, therefore costs of goods are lower. Uptake is more controllable.
- Technology Application
- Therapeutic or life sciences tool platform
- Application Date
- 40704
- Application No.
- PCT/NZ2011/000102
- Others
- We have identified a novel cell penetrating peptide designated Xentry derived from the X-protein of the hepatitis B virus. It is the smallest known carrier peptide -only 5 amino acids in length. It holds a therapeutic advantage in that it is not taken up by non-adherent cells, hence will not be sequestered and diluted by blood cells following injection, thereby enabling more efficient targeting of tissues.
- ID No.
- 1656099
- Country/Region
- New Zealand
For more information, please click Here
